Papers/PMID:41488752
Efficacy of Paroxetine as an Adjuvant Therapy in Rheumatoid Arthritis Patients: A Randomized Controlled Study.
Drug design, development and therapy2025The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
paroxetine — decreases subjective fatigue
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Fatigue scores improved significantly in both groups, but the reduction was larger in the paroxetine group [7.75 (6.9–8.52) → 4.5 (3.27–7.27)] compared to the control group [7.55 (7–8.4) → 5.85 (4.57–8.25); p = 0.006 between groups].”
Quoted verbatim from Efficacy of Paroxetine as an Adjuvant Therapy in Rheumatoid Arthritis Patients: A Randomized Controlled Study.. - Study
- RCT
- Duration
- 3 months
- Dose
- paroxetine 20 mg once daily
- Population
- Adults with active mild or moderate rheumatoid arthritis, all on methotrexate-based csDMARDs and prednisolone 10 mg/day in both arms; paroxetine plus csDMARD versus placebo plus csDMARD; three-month result, intention-to-treat with baseline observation carried forward
Efficacy of Paroxetine as an Adjuvant Therapy in Rheumatoid Arthritis Patients: A Randomized Controlled Study.2025PMID:41488752Permalink